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ABSTRACT
Quantification of BCR-ABL1 mRNA levels in peripheral blood of chronic myeloid 
leukemia patients is a strong indicator of response to tyrosine-kinase inhibitors (TKI) 
treatment. However, additional prognostic markers are needed in order to better 
classify patients. The hypothesis of leukemic stem cells (LSCs) heterogeneity and 
persistence, suggests that their functional evaluation could be of clinical interest. In 
this work, we assessed the primitive and progenitor fractions in patients at diagnosis 
and during TKI treatment using functional in vitro assays, defining a “functional 
leukemic burden” (FLB). We observed that the FLB was reduced in vivo in both 
fractions upon treatment. However, different FLB levels were observed among 
patients according to their response to treatment, suggesting that quantification of 
the FLB could complement early molecular monitoring. Given that FLB assessment is 
limited by BCR-ABL1 mRNA expression levels, we developed a novel detection method 
of primitive cells at the DNA level, using patient-specific primers and direct nested 
PCR in colonies obtained from functional in vitro assays. We believe that this method 
could be useful in the context of discontinuation trials, given that it is unknown 
whether the persistent leukemic clone represents LSCs, able to resume the leukemia 
upon TKI removal.
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INTRODUCTION
Chronic myeloid leukemia (CML) is a hematopoietic 
disorder in which myeloid cells proliferate excessively 
given to the abnormal activation of the chimaeric protein 
BCR-ABL1. The reciprocal translocation t(9;22)(q34;q11) 
gives rise to the fusion gene BCR-ABL1, which encodes 
a constitutively activated protein with tyrosine kinase 
activity [1]. Patients are treated with specific tyrosine-
kinase inhibitors (TKI), such as Imatinib, Nilotinib and 
Dasatinib, and the disease is monitored by measuring the 
level of BCR-ABL1 transcripts in peripheral blood (PB) 
[2]. Despite most patients achieve a good response to 
TKI treatment [3], very low levels of disease can persist 
even after many years of successful treatment, making the 
decision of stopping TKI mostly restricted to clinical trials 
in which patients are closely monitored for rising levels of 
BCR-ABL1 transcripts in PB.
Although treatment duration, deep molecular 
response maintenance, and Sokal score have been 
reported as prognostic factors of molecular relapse after 
TKI withdrawal [4], an explanation for the heterogeneous 
response after treatment discontinuation is still lacking. 
Molecular relapse has been attributed to the persistence 
of leukemic stem cells (LSCs), which are independent 
of BCR-ABL1 kinase activity for survival in short 
term in vitro assays [5–7]. On the other hand, a recent 
report suggests that their elimination in vivo would not 
be a requisite for successful TKI discontinuation [8]. 
However, whether the functionality of residual LSCs can 
vary among patients in deep molecular response remains 
unknown. Their potential relevance is evidenced by the 
great efforts that are being taken in order to develop LSCs-
targeting drugs [9–11]. Therefore, the quantification and 
characterization of LSCs in patients under prolonged TKI 
treatment is of great interest in the context of assessing 
residual disease. This task is specially challenging in 
such patients because of the low frequency of LSCs in 
the hematopoietic system, and their low level of BCR-
ABL1 expression [12]. Therefore, new methods that allow 
greater sensitivity for LSCs detection are needed.
Breakpoints that lead to BCR-ABL1 chimaeric 
gene are dispersed over a ~3kbp region in BCR (intron 
13 or intron 14), and a ~140kbp region in ABL1 (intron 
1). Therefore, each patient harbors a specific genomic 
breakpoint, which requires personalized characterization 
in order to design patient-specific primers for PCR 
detection at the DNA level. Previous reports have shown 
that BCR-ABL1 can be detected at the DNA level in 
patients under sustained deep molecular response, even 
in those that attained a treatment-free remission (TFR) 
after TKI discontinuation [13]. However, it is unknown 
whether the persistent BCR-ABL1-positive cells constitute 
a primitive fraction, i.e. LSCs, with the potential capacity 
of causing disease, or whether they represent a population 
of cells unable to resume the leukemia.
In order to study the dynamics of primitive and 
progenitor fractions, we report the evaluation of such 
populations at the RNA level by functional in vitro assays, 
in CML patients at diagnosis and during TKI treatment. 
In addition, we show that it is possible to detect residual 
primitive cells by in vitro functional assays at the DNA 
level, which enables independence from BCR-ABL1 
expression levels. This method is of potential interest for 
assessing residual disease in future TKI discontinuation 
trials.
RESULTS
Detection based on quantification of BCR-ABL1 
mRNA in primitive and progenitor fractions
Long-term Culture Initiating Cell (LTC-IC) and 
short-term Colony Forming Units (CFU) assays are 
functional in vitro assays that enable to retrospectively 
quantify cells in the primitive and lineage-restricted 
progenitor fraction, respectively. Aiming to evaluate 
whether the dynamics of these populations can vary 
among patients at diagnosis and under TKI treatment, 
we performed both assays with PB or bone marrow 
(BM) samples from CML patients (Table 1). In order to 
distinguish leukemic from normal primitive or progenitor 
cells, we assessed the level of BCR-ABL1 transcripts by 
RT-qPCR in individual or pooled colonies plucked from 
methylcellulose (Figure 1). Whereas initially, detection 
was performed on individual colonies, we observed 
that the evaluation of pooled colonies increased the 
sensitivity of the assay, allowing to scan a higher number 
of colonies per patient, and increasing the yield of RNA 
for subsequent molecular analysis.
Given that the assessment of pooled colonies did 
not allow us to distinguish between the concurrently 
contribution of expression (i.e. BCR-ABL1 mRNA 
levels) and frequency (i.e. number of leukemic cells), 
we considered both factors as a single one, defined as 
primitive or progenitor “functional leukemic burden” 
(FLB). For each patient, the value of FLB was calculated 
as the median of %BCR-ABL1/ABL1 measured in each 
colony or pool of colonies (Figure 1). This definition 
enabled us to distinguish such effects from the previously 
reported “leukemic stem cell burden”, defined as the 
frequency of Philadelphia chromosome-positive cells 
(assessed by FISH) in phenotypically-defined primitive 
fractions sorted by flow cytometry [14, 15].
Results from patients at diagnosis before any 
TKI treatment showed variable levels of FLB both in 
the primitive and progenitor fractions, being higher in 
the latter (mean±SD: 6.3%±13.2% vs. 52.4%±21.5% 
respectively, Mann–Whitney U test, p<0.05, Figure 
2A). As soon as patients underwent TKI treatment, the 
FLB was reduced both in the primitive and progenitor 
fractions (Figure 2B-2D). If we consider the proportion 
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of BCR-ABL1+ single or pooled colonies according to the 
molecular response in PB, the primitive fraction showed 
a slower reduction than progenitor cells during treatment 
(Figure 3).
Early reduction of BCR-ABL1 transcript burden in 
PB, such as BCR-ABL1/ABL1IS ≤ 10% at 3 months, or 
<1% at 6 months, is associated with optimal response 
to first-line TKI treatment [16]. Although most of these 
patients can sustain an optimal response over time (No-
Resistant, NR), a minority of them can develop secondary 
resistance (SR) to treatment. Patients that never responded 
to TKI treatment were considered as primary resistant 
cases (PR, see Materials and Methods for further details). 
Given that additional prognostic markers could be of 
Table 1: Clinical features of patients included in the study
At diagnosis MR1.0-MR2.0 MR3.0-MR5.0
(N=10) (N=13) (N=12)
Age -yr
Median 57 61 66
Range 18-79 36-74 28-74
Female/Male sex, % 30/70 15/85 50/50
Sokal score, no. (%)
Low 4 (44.4) * 5 (38.5) 5 (45.5) **
Intermediate 3 (33.4) * 4 (30.8) 5 (45.5) **
High 2 (22.2) * 4 (30.8) 1 (9) **
TKI, no. (%)
Imatinib n/a 13 (100) 8 (66.7)
Nilotinib 1st line n/a 0 (0) 3 (25)
Nilotinib 2nd line n/a 0 (0) 1 (8.3)
Time of TKI treatment, months
Median n/a 6 20.4
Range n/a 3-9 6-85
At diagnosis, before TKI treatment; MR- Molecular response in PB; n/a- not applicable, *1 missing value, % calculated 
over 9 cases; ** 1 missing value, % calculated over 11 cases
Figure 1: Workflow. Detection of primitive and progenitor fractions at RNA level by in vitro functional assays was performed on patient 
samples at diagnosis and during TKI treatment. Evaluation of the primitive fraction at DNA level was performed as proof of concept on one 
patient (dotted line). BM: bone marrow, PB: peripheral blood, RBC: red blood cell lysis, gDNA: genomic DNA, FLB: functional leukemic 
burden, NGS: next-generation sequencing, LSC: leukemic stem cell
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clinical relevance in order to better predict resistance to 
TKI, we compared the primitive and progenitor FLB from 
both groups at different time points upon TKI treatment.
Despite the fact that at diagnosis we did not observe 
significant differences neither in the progenitor nor in the 
primitive fraction between patients in the NR and PR/SR 
groups (Figure 4), at 6 months of TKI treatment patients 
in the PR/SR group showed significantly higher levels of 
primitive FLB than those in the NR group (p<0.05, Mann–
Whitney U test, Figure 5).
Detection based on amplification of BCR-ABL1 
DNA in the primitive fraction
Regarding the possibility of assessing residual 
disease in patients showing deep molecular response, 
we were not able to detect BCR-ABL1 transcripts in 
most patients with the LTC-IC assay (Table 2). Given 
that detection is limited by the level of expression of 
BCR-ABL1 mRNA by individual colonies, we designed 
patient-specific primers in order to evaluate BCR-ABL1 
rearrangement at the DNA level. A sample of PB at 
diagnosis was used for genomic DNA (gDNA) extraction 
and sequencing of the rearrangement breakpoint by 
long-range multiplex-PCR followed by next-generation 
sequencing (NGS) (Supplementary Figure 1). The patient 
showed declining levels of BCR-ABL1 transcripts in PB 
under Imatinib treatment (400mg daily), attaining a MR3.0 
at 18 months. A PB sample at 18 months of TKI treatment 
was used for CD34+ cells isolation, followed by a 6-weeks-
LTC-IC assay (Figure 1). We assessed the presence of 
BCR-ABL1-positive individual colonies by an in-house 
method of direct nested-PCR, without a gDNA extraction 
step (see Materials and methods). Quality of the starting 
material was evaluated by detecting an independent gene 
at the DNA level, and colonies from a 2-wks-CFU assay 
at 6 months of treatment were used as positive controls. 
Nested PCR showed improved sensitivity compared to 
single PCR (data not shown), and it was able to detect a 
low proportion of BCR-ABL1+ individual colonies in the 
primitive fraction (5 out of 20) (Figure 6).
DISCUSSION
The assessment of individual LTC-IC-derived 
cells is particularly challenging: first, LSCs can be 
Figure 2: FLB in primitive and progenitor fractions at diagnosis and during TKI treatment. Each dot is the median value of 
individual or pooled colonies from each patient: (A) before TKI treatment, (B) at 3 months, (C) at 6 months, and (D) at 12 months of TKI treatment. 
In order to improve visualization, data was log-transformed (zero values were assigned a value of 0.001%, according to the theoretical limit of 
BCR-ABL1/ABL1 detection by RT-qPCR). Statistical analysis was performed before log-transformation. * = p<0.05, Mann–Whitney U test.
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highly quiescent and, therefore, might not generate any 
detectable progeny in these assays [5]. Second, this cell 
population, being in the apex of the hematopoietic system, 
is of very low frequency, emphasizing the methodological 
difficulty in detecting these cells in BM or PB samples. 
In designing the present study, we first sought a method 
that would allow the functional isolation from a CD34+ 
cell population of a viable fraction of stem-like leukemic 
cells. For this, we used the most rigorous in vitro LSC 
detection technique (6-weeks LTC-IC) to evaluate the 
effects of TKI therapies on the most primitive leukemic 
cell compartment. As stated above, we considered the 
FLB to reflect a population of primitive or progenitor 
cells able to self-renew, give rise to daughter cells during 
in vitro functional assays, and produce variable levels 
of BCR-ABL1 mRNA. We had to adopt this definition 
because the evaluation of pooled colonies did not allow 
us to distinguish the effects of variable frequency of BCR-
ABL1-positive colonies, from the effects of variable levels 
of BCR-ABL1 expression among individual colonies. 
Despite this limitation, dynamics of the primitive fraction 
during TKI treatment measured by FLB was comparable 
Figure 3: Percentage of BCR-ABL1+ single or pooled colonies in patients at diagnosis and under TKI treatment, 
according to their molecular response in PB. Individual or pooled colonies were evaluated by RT-qPCR from each patient. 
Horizontal lines show the mean value for each group. NT= at diagnosis, before TKI treatment.
Figure 4: Evaluation of FLB at diagnosis. %BCR-ABL1/ABL1 was measured by RT-qPCR in individual and pooled colonies from 
patients at diagnosis, before any TKI treatment, in the progenitor (left) and primitive (right) fractions. Each dot is the median value of 
individual or pooled colonies from each patient. In order to improve visualization, data from 6-wks-LTC-IC assay was Log-transformed. 
Statistical analysis was performed before log-transformation, n.s: p>0.05, Mann–Whitney U test.
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to previous reports based on phenotypically defined LSCs 
[14, 15], complementing such studies. As far as we are 
concerned, this is the first time that the primitive fraction 
is measured by LTC-IC assays in patients during their first 
year of TKI treatment.
Previous reports suggested that BCR-ABL1 
overexpression in primitive cells (lin-CD34+CD38-) and 
mature (CD34+CD38+) progenitors may contribute to 
the failure of TKIs to prevent disease progression [17]. 
However, disease behavior is very variable for individual 
patients, with some progressing within a few months, 
and others remaining in stable CP for many years. This 
heterogeneity may relate to mutations later acquired in the 
BCR-ABL1 gene, subtype of stem cell in which BCR-ABL1 
is expressed, differences in transcript expression patterns 
between patients, and differential interactions with the BM 
microenvironment and the immune system [18–23]. Here 
we show that, at six months of treatment, the primitive 
FLB in CP CML patients could be a prognostic marker 
correlating with resistance to TKIs. Although a larger 
cohort of patients should be studied in order to confirm 
our observations, these results reinforce previously 
reported data about the impact of LSC burden on TKI 
Figure 5: Primitive FLB in patients at 6 months of TKI treatment. %BCR-ABL1/ABL1 was measured by RT-qPCR in colonies 
from 6-wks-LTC-IC assays. Each dot is the median value of pooled colonies from each patient. In order to improve visualization, data was 
log-transformed (zero values were assigned a value of 0.001%, according to the theoretical limit of BCR-ABL1/ABL1 detection by RT-
qPCR). Statistical analysis was performed before log-transformation. N=4 per group, * = p<0.05, Mann–Whitney U test.
Figure 6: Patient-specific BCR-ABL1 gDNA detection in the primitive fraction. 2.5% agarose gel electrophoresis result from 
nested PCR using patient-specific primers. Estimated size of 2nd-round specific PCR product: 166bp. Lanes 1-20: individual CFU-Cs, 
NC= negative control (surrounding methylcellulose with no CFU-Cs), M: 100-bp molecular weight marker. Lanes 3, 6, 7, 9 and 16 show 
BCR-ABL1+ 2nd-round-PCR product.
Table 2: Percentage of patients with at least one pool 
of colonies positive for BCR-ABL1 mRNA
Molecular response in PB 6-weeks LTC-IC assay




therapy outcome [14, 15], adding new evidence based on 
functional in vitro assays.
The fact that longer treatment is associated with 
lower relapse rates upon TKI interruption suggests that 
the risk of relapse might be related to the achievement 
of certain depth of MR below the detection limit 
of conventional RT-qPCR [24]. In multiple TKI-
discontinuation trials, around 60% of patients relapse, 
whereas 40% can maintain TFR [4]. It has been shown that 
patients that achieve TFR can harbor BCR-ABL1-positive 
clones assessed at the DNA level [13], or at the RNA level 
[8]. However, it is not known whether such persistent 
cells are potentially clonogenic, i.e. LSCs that are able 
to self-renew and give rise to a full leukemic clone, or 
whether they are terminally differentiated cells that could 
survive TKI treatment by some unknown mechanism. 
A third possibility is that the immune system in TFR 
patients allows the presence of LSCs that are not able to 
develop their leukemic potential [25]. For this reason, 
strategies that increase PCR sensitivity for detection of 
residual LSCs may be relevant to better select patients 
with the highest likelihoods of remaining in remission 
without treatment. Although detectable levels of BCR-
ABL1 mRNA in individual colonies from patients with 
undetectable deep molecular response have been reported, 
such levels were very low [26], suggesting that RNA-
based methods will always be limited in patients under 
TKI treatment for long periods of time. In this work, we 
describe a strategy that, combining direct-PCR assessment 
for BCR-ABL1 DNA breakpoint with LTC-IC assay for 
separation of the primitive hematopoietic fraction, enables 
us to measure residual leukemic disease at the LSC level. 
Therefore, this method could be particularly useful in 
situations where the concurrently low burden of leukemic 
primitive cells and very low BCR-ABL1 mRNA expression 
levels, limit the sensitive detection of residual disease. 
With the purpose to validate this strategy, we will apply 
it in a currently recruiting TKI discontinuation trial in 
Argentina; we believe that in the future, this study may 
result of great interest in order to understand patients´ 
heterogeneous capacity of successfully maintaining TFR.
Overall, our results suggest that assessment of BCR-
ABL1 mRNA levels in the primitive fraction during TKI 
treatment could be of clinical utility in order to improve 
and complement molecular monitoring in PB. Finally, 
we propose that the residual leukemic burden should be 
further assessed by gDNA PCR at the LSC level.
MATERIALS AND METHODS
Patient samples
The project was approved by the Institutional 
Review Board, at Instituto Alexander Fleming, Buenos 
Aires, Argentina. After giving written informed consent, 
BM or PB samples were obtained from newly diagnosed, 
untreated CML patients in CP, or from patients at 
different time points during TKI treatment. Mononuclear 
cells were isolated by density-gradient centrifugation 
(Ficoll-Paque PLUS, GE Healthcare Life Sciences) for 
30 minutes at 480xg, followed by one wash in PBS, a red 
cell lysis step (EDTA 0.13mM, KHCO3 1 mM, NH4Cl 
170mM, pH 7.3), and a low-speed centrifugation step 
(12-15 minutes at 200xg) for removal of the platelet-rich 
fraction. Up to 2x108 mononuclear cells were used for 
CD34+ cells isolation. Patients were classified according 
to their response to TKI treatment as follows: patients 
that were not able to achieve early response milestones 
and that would be considered as cases of warning or 
treatment failure according to the European Leukemia 
Net [16], were classified as cases of PR to treatment; 
patients that initially responded to treatment, and met 
early response (3 and 6 months) milestones, but later 
developed intolerance, rising levels of BCR-ABL1 
transcripts, or secondary malignancies, were considered 
as SR patients; patients that sustained the requirements 
to be considered as optimal responders up to 1 year of 
TKI treatment, and did not develop SR events were 
considered as NR patients.
CD34+ cells isolation
In order to enrich samples in the progenitor and 
primitive fraction, we performed a positive selection 
using CD34 MicroBeads (Miltenyi Biotech), according to 
the manufacturer’s instructions. The CD34+ fraction was 
immediately used for functional assays, or cryopreserved 
for later use in freezing medium (DMEM 50%/HSA 40%/
DMSO 10%). When available, 10,000 cells were used for 
purity assessment by flow cytometry.
CFU assay
500 CD34+ cells were plated in duplicate in p35 
culture dishes containing 1mL of enriched methylcellulose 
(Methocult H4435 Medium, Stem Cell Technologies, 
Vancouver, Canada), and incubated at 37°C in a humid 
chamber. After 14-18 days, hematopoietic colonies were 
counted under the microscope, and individual or pooled 
colonies (made of 4 to 6 colonies) were plucked from 
methylcellulose and put into 500μl of RPMI medium 
(GIBCO, Thermo Fisher Scientific). Up to 10 pools of 
colonies were evaluated per patient, depending on the 
yield of the assay. All types of colonies were used for 
RNA isolation (CFU-GM, CFU-M, CFU-G, BFU-E, 
CFU-GEMM), and no differences in BCR-ABL1 mRNA 
expression were found among different types (data not 
shown). After centrifugation, pellets were resuspended in 
100μl of lysis solution (RNAqueous-Micro Kit, Ambion, 




5,000 CD34+ cells were plated in collagen-
coated p35 culture dishes containing 2mL of Long-term 
culture medium (Myelocult supplemented with freshly 
prepared hydrocortisone 10-6 M, both from Stem Cell 
Technologies), over a feeder layer composed of murine 
M2-10B4 and SI/SI cells producing hIL-3, hSCF and 
hGCSF (kindly provided by Stem Cell Technologies), 
previously irradiated at 80Gy. Transfected M2-10B4 and 
SI/SI cells were selected with G418 and Hygromicin 
B every 2 or 3 passages. One half of the medium was 
replaced every week. After 6 weeks, adherent and non-
adherent cells were harvested, and 20,000 cells were used 
for short-term CFU assays, as described above.
RNA extraction and RT-qPCR
Total RNA was extracted from single or pooled 
colonies using RNAqueous-Microkit (Ambion, Thermo 
Fisher Scientific). RNA was eluted in 18μl of elution 
solution at 75°C; only samples with acceptable purity 
(A260/A280 ≥ 1.7) were used for retrotranscription using 
Superscript II (Invitrogen, Thermo Fisher Scientific). 
qPCR was performed using primers and probes for 
BCR-ABL1 and ABL1 from the European against cancer 
program [27]. Absolute quantification was performed 
using a calibration curve from a commercial kit (Molecular 
MD). Total RNA from PB samples was extracted using 
Trizol (Invitrogen, Thermo Fisher Scientific) after 
lysis of red blood cells. Results were harmonized to 
the International Scale by means of a conversion factor 
obtained by standardization with secondary cellular 
calibrators [28]. Some patients were monitored in other 
standardized centers, and so BCR-ABL1/ABL1 ratios were 
obtained directly from their data.
NGS detection of BCR-ABL1 breakpoint
High quality genomic DNA was extracted from 
PB or BM samples from newly diagnosed CML patients 
using DNAzol (Invitrogen, Thermo Fisher Scientific). 
Multiplex long-range PCR was performed using different 
sets of primers as previously described [13]. The PCR 
product was used for library generation in the Ion Torrent 
PGM platform (Thermo Fisher Scientific) according to 
manufacturer’s instructions. Briefly, PCR products were 
fragmented with Ion Shear Plus Reagents and purified 
with Agencourt AMPure XP (Beckman Coulter). Barcoded 
adapters were ligated according to manufacturer’s 
instructions with Ion Xpress Plus Fragment Library 
Kit, and the products were quantified by qPCR. Finally, 
samples were prepared for emulsion PCR, enriched with 
Ion PGM Template OT2 200 Kit, and sequenced using Ion 
318TM Chip v2 with Ion PGM Sequencing 200 Kit v2.
Bioinformatics analysis of NGS data
In order to find the chromosomal translocation 
point, reads were aligned using the Subjunc aligner 
included in the Subread package (v1.5.0-p3) [29] and 
human genome reference UCSC version of the hg19. 
Sorting and indexing were performed with Picard (v1.119) 
(http://broadinstitute.github.io/picard). The fusion points 
were localized using CREST (Clipping Reveals Structure, 
v0.0.1) [30], which relays on soft-clipping signatures for 
identifying breakpoints. Finally, Blast2Seq algorithm was 
used against ABL1 and BCR reference sequences in order 
to identify each segment.
Detection of BCR-ABL1+ cells at DNA level using 
NGS-derived data
Sequence corresponding to patient-specific fusion 
breakpoint was used for PCR primer design (Primer3Plus). 
Short and long-term culture assays were performed as 
described above. Individual colonies were plucked from 
methylcellulose and subjected to direct nested PCR 
without a DNA extraction step. For this, cell lysis was 
performed by plucking individual colonies with a p20 tip 
set at 5μl, into 50 μL of the following mixture: GoTaqFlexi 
PCR buffer (Promega, USA) supplemented with NP-40 
0.5%, Tween-20 0.5%, and proteinase K 0.91 mg/mL. 
Lysates were incubated for 1 hour at 60°C, followed by 
15 minutes at 95°C. 10% of the final volume was used for 
first-round PCR. This PCR product was diluted ten-fold 
for second-round PCR.
Statistical analysis
Data was plotted using GraphPad Prism software or 
R project. Statistical analysis of the data was performed 
with Infostat Software (Córdoba, Argentina). When the 
assumptions of normality and homoscedasticity of the 
data were not met, variance was modeled previous to 
performing a parametric test (ANOVA), or analyzed by 
non-parametric tests (Mann–Whitney U test). A mixed-
effects model was used in ANOVA (response to treatment 
as fixed-effect type, patient as a random-effect type).
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